U.S. flag An official website of the United States government
  1. Home
  2. Animal & Veterinary
  3. Safety & Health
  4. Product Safety Information
  5. Adverse Event Reports for Animal Drugs and Devices
  1. Product Safety Information

Adverse Event Reports for Animal Drugs and Devices

In the spirit of openness and transparency, the FDA’s Center for Veterinary Medicine now makes adverse event reports (AERs) related to animal drugs and devices used in animals available on openFDA.gov, a platform electronically accessible to the general public and available for automated searching. The platform is often used by researchers, statisticians and other academics to access large, valuable public health datasets collected by the FDA.

The AER data received by CVM and uploaded to openFDA.gov include reports associated with approved animal drugs, unapproved/compounded drugs used in animals, and devices used in animals.

CVM’s AER data include adverse events or product defect reports related to animal drugs or devices used in animals. These can include minor to major health events, but also complaints about the off-color of a product, defective packaging, and other non-health-related issues. It’s also important to recognize the information in the database is as reported to the FDA’s CVM, and the agency has not necessarily determined if the product(s) in question was/were the actual cause of the events reported.

The initial dataset on openFDA.gov includes AER data from January 1, 1987 to September 30, 2018. CVM will update the information quarterly to ensure that the public has the most current information available about adverse events reported to CVM in relation to drugs and devices used in animals.

AER Report Description

The primary purpose for maintaining the CVM AER data is to provide an early warning or signaling system to CVM for adverse events not detected during pre-market testing of FDA-approved animal drugs, detection of product manufacturing-related problems, or detection of a problem occurring because of inappropriate or incorrect use of a drug or device used in animals. In some cases, the data also provide a signal that the drug or device, when used in a wider population, may have an unexpected or unintended effect. CVM scientists use the AER data to recognize potential safety risks and make decisions about product safety, which may include changes to the label or other regulatory action.

The Center's AER process takes into consideration confounding factors such as:

  • Dosage
  • Concomitant drug use
  • The medical and physical condition of animals at the time of treatment
  • Environmental and animal management information
  • Product defects
  • Extra-label-uses

CVM supplies AER data to openFDA.gov so that the public can access information about clinical signs that have been reported for these drugs and devices used in animals. OpenFDA.gov provides full sets of downloadable files to a number of high-value, high priority and scalable structured datasets, including adverse events, drug or device product labeling and recall enforcement reports. Application program interfaces (APIs) are also available to assist with data searches.

The AER data received by CVM and uploaded to openFDA.gov includes reports associated with approved animal drugs, unapproved/compounded drugs and devices used in animals.

An API dataset query result cannot be used to estimate the risk associated with the product or compare one drug or device product with another. When looking at the results, be aware that there is no certainty that the reported drug or device caused the adverse event. While a suspected relationship may exist, it is not established and should not be the sole source of information for clinical decision-making or other assumptions about the safety or effectiveness of a product. The adverse event may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources.

In addition, it is important to remember that AERs represent a small percentage of total usage numbers of a product. Commonly used products may have a higher number of reported adverse events due to the higher total number of animals being given the product. In recent years, the FDA has undertaken efforts to increase collection of AERs. Increases in the total number of AERs is likely a result of improved reporting; however, the FDA believes that AERs are still underreported.

For more information on API datasets, see About the openFDA API.

For information on AER reporting, see How to Report Animal Drug Side Effects and Product Problems.

Disclaimer

Any reference to a commercial product, process, service, or company is not an endorsement or recommendation by the U.S. government, the Department of Health and Human Services, the FDA or any of its components. The FDA is not responsible for the contents of any off-site Internet information referenced by or linked to the agency's internet site.

The information provided using this Internet page is only intended to be General Summary Information to the Public. It is not intended to take the place of either the written law or regulations. For an authoritative source, the FDA Regulations are published in the Code of Federal Regulations (CFR), and are available in book format from the Superintendent of Documents, U.S. Government Printing Office. The CFR is also available online at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm.